Hepatocyte transduction

"Hepatocyte transduction" is not a specific molecule or receptor but refers to the process by which viral vectors, particularly adeno-associated virus (AAV) serotypes like AAV3-ST, AAV7, AAV8, and AAV9, deliver genetic material into hepatocytes (liver parenchymal cells).[1][3][4] This process is critical for liver-directed gene therapy targeting metabolic disorders, hemophilia, liver cancer, and hepatitis, where hepatocytes serve as the primary cellular target due to their role in protein synthesis and secretion.[1][3] Efficiency varies by AAV serotype and species; for instance, AAV3-ST and AAV7 show superior transduction of human hepatocytes compared to mouse cells, achieving up to 16-17% efficiency in xenograft models, influenced by factors like hepatocyte growth factor receptor interactions and vector escape from proteasomal degradation.[1][4] Transduction involves vector uptake via liver sinusoids, navigating fenestrae in endothelial cells, and avoiding clearance by Kupffer cells.[3] It is not a therapeutic target itself but a goal in developing AAV vectors for clinical trials, with challenges including species-specific differences and immune responses limiting long-term expression.[1][2][8] No drugs directly target "hepatocyte transduction" as an entity; instead, engineered AAV capsids optimize it.[1][4]